<DOC>
	<DOC>NCT00288379</DOC>
	<brief_summary>To compare the effects of formoterol alone (Oxis® TurbuhalerÒ) and the fixed combination of formoterol and budesonide (Symbicort® TurbuhalerÒ) on airway responsiveness as a marker of inflammation, induced by repeated low-dose allergen challenge in allergic patients with mild asthma</brief_summary>
	<brief_title>SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>A diagnosed history of asthma for at least 6 months Mild and stable asthma, only using β2agonists as needed for the last 4 weeks. FEV1 &gt;70% of predicted normal value (postbronchodilator value). Skin prick test positive to pollen, animal dander or house dust mite. Any significant respiratory disease, other than asthma. Upper or lower respiratory tract infection within 4 weeks before inclusion. Use of: 1. inhaled glucocorticosteroid treatment for the last 8 weeks prior to inclusion or ever used oral glucocorticoid treatment for asthma. 2. inhaled longacting or oral b2agonists, anticholinergic bronchodilators, cromones, antihistamines, theophyllines and antileukotrienes within 2 weeks of screening. 3. regular NSAIDs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Asthma</keyword>
	<keyword>allergen challenge</keyword>
	<keyword>airway responsiveness</keyword>
	<keyword>airway inflammation</keyword>
	<keyword>Symbicort®</keyword>
</DOC>